Streamlining assessment of pathological response after neoadjuvant treatment
Neoadjuvant immunotherapy continues to transform outcomes for people with melanoma and other cancers. Two recent papers show that assessing pathological response after neoadjuvant immunotherapy can be both more efficient and more consistent, without compromising accuracy.
